AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29353339 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightweight polypropylene mesh
Number of subjects: 363
Study 29353339 — intervention group
Group type: COMPARATOR
Intervention: Heavyweight polypropylene mesh
Number of subjects: 363
Study 29354050 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise intervention
Number of subjects: 0
Study 29354720 — intervention group
Group type: EXPERIMENTAL
Intervention: Toric implantable collamer lens (TICL) implantation after corneal collagen crosslinking
Number of subjects: 24
Study 29355075 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 119
Study 29355224 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA
Number of subjects: 7800
Study 29355224 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper T 380A intrauterine device
Number of subjects: 7800
Study 29355224 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel implant
Number of subjects: 7800
Study 29355412 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride in office (drops/tablets and/or varnish) applied by a health care professional by age 1 y
Number of subjects: 1325
Study 29355412 — intervention group
Group type: COMPARATOR
Intervention: Control group (children who did not receive fluoride in office)
Number of subjects: 1325
Study 29355439 — intervention group
Group type: EXPERIMENTAL
Intervention: Minidose glucagon (150 μg, increased to 300 μg if needed)
Number of subjects: 7
Study 29355439 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia prediction algorithm
Number of subjects: 7
Study 29355439 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon administration
Number of subjects: 7
Study 29355904 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate gel, 0.015% for face/scalp and 0.05% for trunk/extremities, applied for treatment of AK
Number of subjects: 77
Study 29356347 — intervention group
Group type: EXPERIMENTAL
Intervention: EBFSS scale developed from Hughes' Breastfeeding Social Support Scale, validated at 1 and 3 months postpartum.
Number of subjects: 475
Study 29356365 — intervention group
Group type: EXPERIMENTAL
Intervention: TRIP (risk network tracing)
Number of subjects: 1252
Study 29356365 — intervention group
Group type: COMPARATOR
Intervention: IBBS (respondent-driven sampling)
Number of subjects: 1252
Study 29356365 — intervention group
Group type: COMPARATOR
Intervention: Outreach Testing
Number of subjects: 1252
Study 29356365 — intervention group
Group type: EXPERIMENTAL
Intervention: TRIP (recently-infected participants' networks)
Number of subjects: 1252
Study 29356365 — intervention group
Group type: EXPERIMENTAL
Intervention: TRIP (longer-term infected participants' networks)
Number of subjects: 1252
Study 29356607 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise (supervised moderate-to-vigorous 65% to 85% of heart rate maximum, three times per week for 16 weeks)
Number of subjects: 100
Study 29356607 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise
Number of subjects: 100
Study 29356607 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 29356832 — intervention group
Group type: EXPERIMENTAL
Intervention: Short DAPT (≤6 months)
Number of subjects: 517
Study 29356832 — intervention group
Group type: COMPARATOR
Intervention: Long DAPT (12 months)
Number of subjects: 517
Study 29357099 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for mean 21 weeks (sd 5, range 8-24)
Number of subjects: 30
Study 29357718 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 0
Study 29357718 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study 29357821 — intervention group
Group type: EXPERIMENTAL
Intervention: Dining Environment Audit Protocol (DEAP)
Number of subjects: 639
Study 29357826 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair muscle strength training twice a week for 12 weeks
Number of subjects: 64
Study 29357826 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 64
Study 29357841 — intervention group
Group type: EXPERIMENTAL
Intervention: ZIKV RNA presence testing in various body fluids (blood, urine, semen, vaginal secretion/menstrual blood, rectal swab, oral fluids, tears, sweat, breast milk)
Number of subjects: 0
Study 29357841 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-infection testing for dengue, Chikungunya, HIV, hepatitis B and C, syphilis
Number of subjects: 0
Study 29357841 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunological response testing (including IgM and IgG)
Number of subjects: 0
Study 29357841 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque reduction neutralization test for ZIKV and dengue
Number of subjects: 0
Study 29357841 — intervention group
Group type: EXPERIMENTAL
Intervention: ZIKV culture and RNA sequencing
Number of subjects: 0
Study 29357861 — intervention group
Group type: EXPERIMENTAL
Intervention: Stemless humeral head arthroplasty
Number of subjects: 73
Study 29357940 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (psychological preparation and distraction strategy)
Number of subjects: 57
Study 29357940 — intervention group
Group type: COMPARATOR
Intervention: Baseline group (no intervention)
Number of subjects: 57
Study 29358182 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 0
Study 29358183 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide-based therapy
Number of subjects: 288
Study 29358426 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial diffusion-weighted imaging (DWI) lesions
Number of subjects: 122
Study 29358426 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical grey matter (cGM) lesions
Number of subjects: 122
Study 29358426 — intervention group
Group type: EXPERIMENTAL
Intervention: DWI lesions area size
Number of subjects: 122
Study 29358426 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute FLAIR-visibility
Number of subjects: 122
Study 29358426 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall DWI-positive patients
Number of subjects: 122
Study 29358500 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus Pegylated Interferon alfa-2b
Number of subjects: 0
Study 29358500 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus Ipilimumab
Number of subjects: 0
Study 29358500 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29358950 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 230
Study 29358950 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 230
Study 29358961 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture (VA) group 1 (3 times weekly for 4 weeks)
Number of subjects: 30
Study 29358961 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture (VA) group 2 (twice weekly for 4 weeks)
Number of subjects: 30
Study 29358961 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture group (SA; twice weekly for 4 weeks)
Number of subjects: 30
Study 29358961 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including healthy controls)
Number of subjects: 30
Study 29359452 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon undilatable CTOs
Number of subjects: 415
Study 29359452 — intervention group
Group type: EXPERIMENTAL
Intervention: High pressure balloon inflations
Number of subjects: 415
Study 29359452 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational atherectomy
Number of subjects: 415
Study 29359452 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser
Number of subjects: 415
Study 29359452 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting balloons
Number of subjects: 415
Study 29359461 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional and physical performance parameters
Number of subjects: 517
Study 29359461 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoalbuminaemia
Number of subjects: 517
Study 29360184 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent post-transplantation cyclophosphamide (PTCy) for MBM grafts
Number of subjects: 200
Study 29360184 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCy, tacrolimus, and mycophenolate mofetil (MMF) 30 mg/kg for MPBSC grafts
Number of subjects: 200
Study 29360184 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCy, tacrolimus, and MMF 45 mg/kg for MMG grafts
Number of subjects: 200
Study 29360184 — intervention group
Group type: COMPARATOR
Intervention: Combination arms (PTCy, tacrolimus, and MMF)
Number of subjects: 200
Study 29360291 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial Electrotherapy Stimulation (CES) for 20 minutes
Number of subjects: 50
Study 29360414 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalated BEACOPP with or without rituximab
Number of subjects: 782
Study 29360414 — intervention group
Group type: COMPARATOR
Intervention: ABVD
Number of subjects: 782
Study 29360414 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy after chemotherapy
Number of subjects: 782
Study 29360414 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival of all patients
Number of subjects: 782
Study 29360462 — intervention group
Group type: EXPERIMENTAL
Intervention: Large SPSS (L-SPSS, ≥8 mm)
Number of subjects: 1729
Study 29360462 — intervention group
Group type: EXPERIMENTAL
Intervention: Small SPSS (S-SPSS, <8 mm)
Number of subjects: 1729
Study 29360462 — intervention group
Group type: COMPARATOR
Intervention: Without SPSS (W-SPSS)
Number of subjects: 1729
Study 29360462 — intervention group
Group type: EXPERIMENTAL
Intervention: SPSS (both L-SPSS and S-SPSS)
Number of subjects: 1729
Study 29360462 — intervention group
Group type: EXPERIMENTAL
Intervention: SPSS with MELD scores of 6-9
Number of subjects: 1729
Study 29360462 — intervention group
Group type: EXPERIMENTAL
Intervention: SPSS with MELD scores of 10-13
Number of subjects: 1729
Study 29360462 — intervention group
Group type: EXPERIMENTAL
Intervention: SPSS with MELD scores of 14 or more
Number of subjects: 1729
Study 29360526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib therapy, short-term, dosage and duration not specified
Number of subjects: 0
Study 29360987 — intervention group
Group type: EXPERIMENTAL
Intervention: AtriClip PRO device for left atrial appendage (LAA) occlusion
Number of subjects: 40
Study 29361097 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.8 g/day multimatrix mesalamine for 8 weeks (induction period)
Number of subjects: 717
Study 29361097 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4 g/day multimatrix mesalamine for 12 additional months (maintenance period)
Number of subjects: 717
Study 29361097 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluctuating between complete and partial remission during maintenance treatment
Number of subjects: 717
Study 29361134 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted capture sequencing
Number of subjects: 222
Study 29361268 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventral gamma capsulotomy
Number of subjects: 55
Study 29361435 — intervention group
Group type: EXPERIMENTAL
Intervention: SGM-101 (10 mg) administered intravenously 4 days before surgery
Number of subjects: 26
Study 29361444 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional incomplete revascularization (IR) group (rFSS ≥1)
Number of subjects: 385
Study 29361444 — intervention group
Group type: COMPARATOR
Intervention: Functional complete revascularization (CR) group (rFSS = 0)
Number of subjects: 385
Study 29361444 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual functional SYNTAX score (rFSS)
Number of subjects: 385
Study 29361444 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined anatomic and physiological scoring system (rFSS)
Number of subjects: 385
Study 29361470 — intervention group
Group type: EXPERIMENTAL
Intervention: Prexasertib 105 mg/m administered intravenously
Number of subjects: 28
Study 29361484 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29361843 — intervention group
Group type: EXPERIMENTAL
Intervention: Online advertising (Facebook advertisements)
Number of subjects: 406
Study 29361843 — intervention group
Group type: COMPARATOR
Intervention: Community fairs
Number of subjects: 406
Study 29361843 — intervention group
Group type: COMPARATOR
Intervention: Direct mail
Number of subjects: 406
Study 29361843 — intervention group
Group type: COMPARATOR
Intervention: Periodicals
Number of subjects: 406
Study 29361843 — intervention group
Group type: EXPERIMENTAL
Intervention: Online advertising targeting general population
Number of subjects: 406
Study 29361843 — intervention group
Group type: EXPERIMENTAL
Intervention: Online advertising targeting under-represented populations
Number of subjects: 406
Study 29361917 — intervention group
Group type: EXPERIMENTAL
Intervention: M1 macrophages infiltration in tumor islets
Number of subjects: 80
Study 29361917 — intervention group
Group type: EXPERIMENTAL
Intervention: Total M2 macrophages infiltration in tumor (islets and stroma)
Number of subjects: 80
Study 29361934 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text message adherence support intervention for high blood pressure
Number of subjects: 0
Study 29361934 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29362233 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29362251 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of key performance measures such as time to first ECG, receipt of troponin testing, receipt of reperfusion therapy for ST segment elevation ACS, provision of angiography for troponin-positive patients.
Number of subjects: 10000
Study 29362251 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of secondary outcomes including revisit to ED and rehospitalisation within 30 days.
Number of subjects: 10000
Study 29362665 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol (Vitamin D receptor activation)
Number of subjects: 0
Study 29362665 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29362685 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine fixed-dose combination tablets (ASAQ Winthrop®)
Number of subjects: 480
Study 29362724 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal antiretroviral therapy adherence (<100%)
Number of subjects: 0
Study 29362724 — intervention group
Group type: COMPARATOR
Intervention: Optimal antiretroviral therapy adherence (≥100%)
Number of subjects: 0
Study 29363050 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine pharmacokinetics in children aged 1.7 years
Number of subjects: 0
Study 29363050 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine pharmacokinetics in older adults (> 65 years)
Number of subjects: 0
Study 29363050 — intervention group
Group type: EXPERIMENTAL
Intervention: Allometric pharmacokinetic model
Number of subjects: 0
Study 29363050 — intervention group
Group type: EXPERIMENTAL
Intervention: Comedications (Carbamazepine, Phenytoin, Valproic Acid)
Number of subjects: 0
Study 29363235 — intervention group
Group type: EXPERIMENTAL
Intervention: E7777 (6, 12, and 9 μg/kg/day)
Number of subjects: 13
Study 29363235 — intervention group
Group type: EXPERIMENTAL
Intervention: E7777 (9 μg/kg/day)
Number of subjects: 13
Study 29363235 — intervention group
Group type: EXPERIMENTAL
Intervention: E7777
Number of subjects: 13
Study 29363250 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily
Number of subjects: 28
Study 29363343 — intervention group
Group type: EXPERIMENTAL
Intervention: Fevipiprant (QAW039)
Number of subjects: 0
Study 29363343 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29363446 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent dengue DNA vaccine (TVDV) formulated in Vaxfectin
Number of subjects: 0
Study 29363651 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC) consisting of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuffs on bilateral upper limbs twice a day for 90 days.
Number of subjects: 165
Study 29363760 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchrony traces (2D-3D inference method)
Number of subjects: 53
Study 29363760 — intervention group
Group type: COMPARATOR
Intervention: Calypso traces (2D-3D inference method)
Number of subjects: 53
Study 29363760 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaussian PDF method
Number of subjects: 53
Study 29363760 — intervention group
Group type: EXPERIMENTAL
Intervention: Kalman filter
Number of subjects: 53
Study 29363760 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdimensional correlation method
Number of subjects: 53
Study 29363760 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbitrary-shape PDF method
Number of subjects: 53
Study 29363760 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking error
Number of subjects: 53
Study 29363760 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdimensional correlation and BPI
Number of subjects: 53
Study 29364548 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin 100 mg/d (adults) and 2 mg/kg/d (paediatrics)
Number of subjects: 685
Study 29364548 — intervention group
Group type: COMPARATOR
Intervention: L-AmB 3 mg/kg/d
Number of subjects: 685
Study 29364548 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin 100 mg/d and 150 mg/d
Number of subjects: 685
Study 29364548 — intervention group
Group type: COMPARATOR
Intervention: Caspofungin 70 mg/d followed by 50 mg/d
Number of subjects: 685
Study 29364592 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondirected uterus donation
Number of subjects: 6
Study 29364886 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC01LS intravenous (IV) infusion at 20 mg/kg
Number of subjects: 37
Study 29364886 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC01LS intravenous (IV) infusion at 40 mg/kg
Number of subjects: 37
Study 29364886 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC01LS intravenous (IV) administration at 5 mg/kg
Number of subjects: 37
Study 29364886 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC01LS subcutaneous (SC) administration at 5 mg/kg
Number of subjects: 37
Study 29364886 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC01LS IV dose range of 5-40 mg/kg
Number of subjects: 37
Study 29364886 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC01LS
Number of subjects: 37
Study 29364998 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiological signs of pulmonary congestion (assessed by a radiological score on digital chest X-rays) before the spontaneous breathing trial (SBT)
Number of subjects: 170
Study 29364998 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiological findings of pulmonary congestion
Number of subjects: 170
Study 29365099 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 µg administered by subcutaneous injection daily for 104 weeks
Number of subjects: 20
Study 29366329 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate magnetic resonance imaging (MRI)
Number of subjects: 0
Study 29366329 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29366510 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted treatment based on molecular alterations identified from tumor biopsy
Number of subjects: 0
Study 29366580 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary biomarkers (neutrophil gelatinase-associated lipocalin, midkine, interleukin 6)
Number of subjects: 200
Study 29366580 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil gelatinase-associated lipocalin positive/RIFLE-positive
Number of subjects: 200
Study 29366580 — intervention group
Group type: EXPERIMENTAL
Intervention: Midkine-positive/RIFLE-positive
Number of subjects: 200
Study 29366580 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil gelatinase-associated lipocalin or interleukin 6 positive
Number of subjects: 200
Study 29366580 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-biomarker-positive subclinical AKI
Number of subjects: 200
Study 29366960 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000-1250 mg/kg over 30-60 min i.v infusion)
Number of subjects: 285
Study 29367186 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook advertising campaign
Number of subjects: 621
Study 29367186 — intervention group
Group type: COMPARATOR
Intervention: Traditional recruitment methods
Number of subjects: 621
Study 29367212 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiosphere-derived cells (CDCs) infusion
Number of subjects: 101
Study 29367212 — intervention group
Group type: COMPARATOR
Intervention: Staged palliation alone (Control)
Number of subjects: 101
Study 29367268 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 1008
Study 29367293 — intervention group
Group type: EXPERIMENTAL
Intervention: T2 magnetic resonance (T2MR) assay
Number of subjects: 0
Study 29367293 — intervention group
Group type: COMPARATOR
Intervention: Blood culture
Number of subjects: 0
Study 29368166 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term physical activity (exercise within the calculated training pulse) for 8 months
Number of subjects: 98
Study 29368166 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurement of serum sRAGE levels
Number of subjects: 98
Study 29368271 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CCP2 antibody positive patients (Gp1-3)
Number of subjects: 149
Study 29368271 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing anti-CCP2 titer groups (Gp1-3)
Number of subjects: 149
Study 29368271 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with low DXR-BMD
Number of subjects: 149
Study 29368271 — intervention group
Group type: COMPARATOR
Intervention: Anti-CCP2 antibody negative patients
Number of subjects: 149
Study 29368313 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedside transthoracic echocardiography (TTE) with a bubble study to detect PFO
Number of subjects: 202
Study 29368632 — intervention group
Group type: EXPERIMENTAL
Intervention: suPAR levels in patients with CAP
Number of subjects: 282
Study 29368632 — intervention group
Group type: EXPERIMENTAL
Intervention: syndecan-4 levels in patients with CAP
Number of subjects: 282
Study 29368632 — intervention group
Group type: EXPERIMENTAL
Intervention: suPAR for predicting mortality in SCAP
Number of subjects: 282
Study 29368632 — intervention group
Group type: EXPERIMENTAL
Intervention: syndecan-4 for predicting mortality in SCAP
Number of subjects: 282